Catyalyst Pharmaceutical Partners (CPRX) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CPRX Hot Sheet
Price: $31.49 --0%
Financial Fact:
Total operating costs and expenses: 3.91M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Total operating costs and expenses: 3.91M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Catyalyst Pharmaceutical Partners (NASDAQ: CPRX) reported Q2 EPS of ($0.05), $0.02 better than the analyst estimate of ($0.07).
For earnings history and earnings-related data on Catyalyst Pharmaceutical Partners (CPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CPS Technologies (CPSH) Reports In-Line Q3 EPS
- Leidos Holdings (LDOS) PT Lowered to $138 at Stifel
- Amgen (AMGN) PT Raised to $530 at UBS
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
